RxDoctor Payments Data

Abiodun Badewa

Family Medicine · Bessemer, ALNPI 1558562603

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 63 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$644
  • AstraZeneca$170
  • Shield Therapeutics Inc$34
  • Dexcom, Inc.$31
  • Pfizer$30
  • Galt Pharmaceuticals, LLC$20
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK41$644
AstraZeneca10$170
Shield Therapeutics Inc2$34
Dexcom, Inc.1$31
Pfizer2$30
Galt Pharmaceuticals, LLC1$20
Boehringer Ingelheim1$19
Genentech USA, Inc.1$19
Novartis1$18
Scynexis, Inc.1$16
Zyla Life Sciences, Inc.1$13
Biogen1$12

How this compares

$1,026 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$49,893
Medicare patients
274
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$47,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$37,353
JanuviaSitagliptin Phosphate26$20,124
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,933
LinzessLinaclotide20$10,794
Restasis MultidoseCyclosporine11$9,024
SymbicortBudesonide/Formoterol Fumarate21$4,925
Albuterol Sulfate HfaAlbuterol Sulfate164$3,717
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,629
Naproxen88$1,543
Ibuprofen139$1,175
Dexamethasone109$1,174
Losartan Potassium153$1,165
Atorvastatin Calcium113$1,120
Amlodipine Besylate181$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$47,51057 claims
GSKTrelegy Ellipta$644$37,35358 claims
AstraZenecaBreztri Aerosphere, Symbicort$170$15,85732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →